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Background: The aim of this study was to describe the perceptions of married men about 
barriers to accessing and accepting highly active antiretroviral therapy (HAART) by pregnant/
postnatal women positive for human immunodeficiency virus (HIV) and registered in Kabarole 
District’s Program for the Prevention of HIV from Mother to Child (PMTCT-Plus).
Materials and methods: Our study was a qualitative descriptive exploratory study using 
thematic analysis. Four focus group discussions were held with a convenience sample of 
40 married men.
Results: Lack of disclosure of a positive HIV diagnosis to the partner and stigmatization of 
persons with HIV were two major obstacles for women in accessing HAART. In addition, 
men felt that their low knowledge of HAART and their low HIV testing rate also constituted 
  important barriers to these women taking treatment. Men complained that they were not 
  sufficiently involved in the reproductive care of women and that couples’ counseling could be 
a step towards addressing this problem.
Conclusion: Barriers to HAART experienced by pregnant/postnatal women need to be 
addressed in order to improve their uptake of treatment, increase their low treatment  coverage, 
improve their survival, and at the same time dramatically reduce HIV transmission from mother 
to child.
Keywords: men, highly active antiretroviral therapy, pregnant women, Uganda
Introduction
Factors that hinder access to highly active antiretroviral therapy (HAART) among both 
men and women living in sub-Saharan Africa have been well described. Barriers to 
accessing HAART among men and women identified in the literature included cost 
of transportation to the clinic, other treatment costs, complicated HAART regimes, 
language barriers between patients and health staff, adverse reactions to HAART, 
overcrowded health care systems, overworked clinic staff, and lack of knowledge 
about HAART procedures.1–7
HAART coverage for pregnant women in developing countries is much lower 
compared with that of the general population of patients with human immunode-
ficiency virus (HIV) and is reported to be only 15%.8 Similarly, although HAART 
coverage of all eligible HIV patients in Uganda is 43%,8 only 7082 (17%) of 46,948 
eligible pregnant women in Uganda received HAART in 2008–2009.9 In an effort to 
expand HAART uptake by pregnant/postnatal women and to reduce mother-to-child 
transmission of HIV, the Ugandan PMTCT-Plus (Prevention of Mother to Child 
Transmission of HIV) program was established. The PMTCT program consists of free 
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HIV counseling and testing, single-dose nevirapine and/or 
free HAART to eligible HIV-positive mothers and family 
members, using eligibility criteria according to the national 
guidelines for HAART.10 Despite the Ugandan government’s 
efforts to scale up PMTCT-Plus programs from 2003 to 2006, 
Uganda data included in the last country report on HIV/AIDS 
in 2010 indicate that HAART coverage remains low in 
pregnant/postnatal women attending PMTCT-Plus clinics, 
resulting in 25,000 new pediatric HIV infections nationwide 
due to mother-to-child transmission in 2008.11
Few studies involving pregnant/postnatal women have 
reported reduced access to HAART or refusal to utilize 
HAART compared with nonpregnant/postnatal women, or 
men.5,12,13 Also of importance is that very little is known 
about the male perspective on PMTCT and the role men 
play in their partners’ HAART access and uptake.14,15 This 
is particularly important in traditional patriarchal sub-
Saharan African societies, and particularly in Uganda, 
where men are often responsible for household decisions, 
including health-related and health-seeking behaviors for 
their dependent wives and children. Therefore, it is crucial 
to understand men’s perceptions about HAART and its 
benefits, especially for pregnant women, given its potential 
to reduce mother-to-child transmission of HIV . Two stud-
ies from Uganda and Tanzania reported male involvement 
in components of the PMTCT program,14,15 and concluded 
that male involvement in PMTCT programs was low, and 
that there was an urgent need to explore male perceptions 
of PMTCT services further. Despite this, our PubMed 
search revealed no studies that investigated men’s percep-
tion of HAART services for pregnant/post-natal women in 
sub-Saharan Africa, which increases the importance of the 
study we have conducted.
To address this gap in knowledge surrounding barriers 
to accessing HAART among pregnant/postnatal women, 
we undertook a study in Kabarole District, western Uganda, 
between September 2006 and December 2006, with a sample 
of men from urban and rural areas. This study component 
was part of a larger study investigating barriers to HAART 
uptake by pregnant women from the viewpoint of women 
and men.16 In the quantitative part focusing on women’s 
barriers, economic reasons (primarily high transport costs), 
followed by HIV-related stigma, nondisclosure of HIV status 
between partners, long clinic waiting times, and suboptimal 
provider-patient interactions at the PMTCT-Plus clinic 
were reported. The qualitative study presented here sought 
to expand upon our previous findings by reporting men’s 
perspective on the issue.
The two specific objectives of our study were to explore and 
describe the views of married men on barriers to free HAART 
among pregnant/postnatal women in Kabarole District and 
to analyze the main reasons for low HAART uptake among 
pregnant/postnatal women from the perspective of married 
men and contrast the responses from men with the responses 
from women given in the quantitative study component.16
Materials and methods
Our study was a qualitative descriptive exploratory study with 
thematic analysis. Data were collected through four focus 
group discussions with 40 participants. Utilizing a qualitative 
methodology, we undertook extensive discussions among 
participants that revealed men’s perceived barriers to HAART 
access by their female partners in a way that may not have 
been obtained from solely quantitative methodologies.
Study setting
Kabarole’s PMTCT-Plus programs were first launched in 
2003 in five hospitals in the district. These hospitals are 
attended by 13,000 women per year, approximately 8% of 
whom are HIV-positive. Kabarole District’s PMTCT-Plus 
program at the regional hospital experiences a low uptake 
of HAART among eligible PMTCT-Plus clients, with 
approximately one quarter of the clients on HAART lost to 
follow-up in 2006, according to information from the District 
Health Office. Kabarole District has an estimated population 
of 400,000, approximately 20,000 of which are pregnant 
women at any given point in time.17 The district’s population 
is characterized as low-income, with subsistence farming 
representing the main source of income.   Approximately 
74% of the population resides in rural areas, distant from 
urban hospitals and health clinics.
Study sample
Forty participants for the four focus group discussions were 
selected by convenience sampling from both urban and rural 
areas. Inclusion criteria for the focus group discussions were 
being male and married or having a female partner within 
the 18–45-year age group. Participants were fully briefed 
on the study prior to enrollment. Demographic information 
for the participants is shown in Table 1. The local admin-
istration provided a quiet interview space for focus group 
discussions to avoid noise interference and interruptions.
Study instrument
The focus group discussion guide topics were derived with 
input from the literature and the knowledge/perceptions 
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of local health care workers involved in the PMTCT-Plus 
program. Discussion topics included knowledge of HIV and 
HAART, willingness to be tested for HIV , HIV serostatus 
disclosure between partners, social support, and perceived 
reasons for the low uptake of free HAART by pregnant/
postnatal women. The participants were not asked about their 
own HIV status. It was also made clear to the participants 
before the focus group discussions started, that the topic 
of discussion was not single-dose nevirapine, but lifelong 
antiretroviral combination drug therapy, ie, HAART.
Data collection and analysis
The focus group discussions were conducted using the 
  interview guide, developed with open-ended questions. 
The focus group discussions were moderated by the first 
author with a research assistant experienced in qualitative 
  methodology, who provided simultaneous translation from 
Rutooro (the local language) into English. The interviews 
were audiotaped with the consent of the participants. The focus 
group discussions lasted on average about 80 minutes each. 
Tapes were transcribed verbatim in Rutooro and were subse-
quently translated into English. Spot checks of transcripts and 
translations were regularly conducted to ensure completeness 
of the transcription and accuracy of translation.
Data analysis for the focus group discussions was conducted 
using principles of thematic analysis.18,19 This included multiple 
overall surface readings of transcripts to capture context and 
meaning, followed by coding and categorization of recurring 
concepts/ideas. A master list of all categories was assembled 
and examined for common themes. Categories of codes were 
then organized into overarching themes. Data verification 
was done by a second researcher coding all transcripts. Codes 
were compared and added or removed based by agreement. 
The results of our interviews were also compared with the 
literature and verified with participants. Following coding, a 
frequency distribution list was developed, and the number of 
responses for each category of participants was recorded and 
tallied. Quotations selected were those which best represented 
the ideas voiced by participants and were also chosen based on 
the frequency with which they were mentioned.
Ethical considerations
Ethical and administrative approval of the study method-
ology was sought and granted from the Health Research 
Ethics Board at the University of Alberta, Edmonton, 
Canada, the Ugandan Council for Science and   Technology, 
Kampala, Uganda, and the District Health Officer, 
Kabarole District, Fort Portal, Uganda. Informed consent 
was obtained from each participant prior to the interview 
by reading and providing an information letter and sign-
ing a consent form. Participants received a small amount 
(between $1 and $2) to assist with transport to participate 
in the study.
Results
The four main themes extracted from the data were lack of 
HAART knowledge among males, low HIV testing in males, 
women’s lack of trust in confidentiality when on HAART, 
and fears of serostatus disclosure to their partners.
Lack of HAART knowledge among males
Although most study participants were cognizant of 
HAART, their level of knowledge seemed to be very basic 
and incomplete. There were about one or two participants 
in each focus group who had never heard of HAART 
before. The following focus group discussion excerpts 
exemplify the typical responses obtained regarding HAART 
knowledge:
	 “Advise us about HAART. Some of us we don’t know 
anything about these drugs, so teach us so we can know 
something.”
	 “Women are sensitized when they go for antenatal care. 
Men should also be sensitized by all means so they can 
test.”
Misconceptions about HAART were also expressed, eg, 
that antiretroviral drugs cause weakness sometimes leading 
to death of HIV patients. This common misconception was 
mentioned by multiple respondents in all four of the male 
interviews, as indicated in the following passage: “[People] 
said that when you start on these drugs and then you stop you 
can even die and this is one of the reasons as to why people 
have feared to go and test to get the drugs.”
The most common question raised in all four focus group 
discussions was whether or not HAART cures HIV/acquired 
immune deficiency syndrome (AIDS):
	 “We hear that [HAART] reduces the virus in the body and 
you live a bit longer but what I don’t know is whether it 
totally cures AIDS so I beg you to explain more and let 
us know the truth about these drugs.”
Table 1 Demographic characteristics of 40 male focus group 
discussion participants
Group 1 Group 2 Group 3 Group 4
Participants, n 9 10 9 12
Mean (range)  
age, years
28 (18–35) 32 (19–41) 28 (18–40) 28 (18–39)
Residence Urban Urban Rural Rural
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	 “If I am 30 years old but the disease has eaten me up and 
I am only left with maybe two years to die, if I start taking 
those drugs, will I be cured?”
Many respondents articulated that, unlike women, who 
are counseled in antenatal clinics, men lack the opportunity 
to be taught about HIV/AIDS and HAART.
Low HIV testing among men
Many respondents felt that a lack of HIV/AIDS and HAART 
knowledge among men may contribute to their low uptake 
of HIV testing. In addition, economic reasons for not being 
HIV tested were mentioned, as shown in the following 
responses:
	 “Some of us don’t have transport and we hesitate going 
to far places for testing.”
	 “Even there at the sub-county health unit they charge 
two thousand five hundred shillings (approximately $1 
US) per head. So if you are to go with your wife that’s 
five thousand, which we don’t have – that also makes us 
reluctant. We have other problems and requirements at 
home.”
The latter excerpt expresses a sentiment that was repeated 
by many other respondents, ie, that being tested interferes 
with their ability to work and is often regarded as a nui-
sance rather than a priority. The following comment by one 
participant implies that an HIV-positive diagnosis resulting 
from testing creates worries that can also interfere with one’s 
ability to work:
	 “Men do a lot of hard work – working from morning until 
late in the evening, so they say when they test and maybe 
they are HIV-positive they will have many worries and they 
will not be able to work. That is why they don’t test.”
Women lack trust in confidentiality  
when on HAART
Our results suggest that participants were well aware of men’s 
influence on their partners’ decision to take HAART. Men 
also speculated that HAART uptake by pregnant/postnatal 
women may avoid taking HAART to conceal their HIV-
positive diagnosis from their partners, as follows:
	 “The woman fears maybe because she still loves the 
husband and maybe they have children so she decides 
to keep quiet to avoid conflicts at home because she 
fears the man might say she is the one who brought the 
disease.”
	 “Some women are beaten by their husbands at times for 
no good reason if then he saw you swallowing drugs, he’d 
kill her.”
Fear of violence as a barrier to disclosure and HAART 
acceptance was cited by several participants. Participants 
also explained that, because many women depend on their 
partners for economic support, abandonment as a result of an 
HIV-positive status disclosure would eliminate this monetary 
resource on which they rely for survival:
	 “She fears if the man comes to know about it, she can 
divorce her and you know people are poor, she will start 
suffering with no-one to help her. Poverty is the problem. 
If someone knows she can support herself without the 
man then she can start the drugs without even telling the 
husband.”
Another factor that men indicated may inhibit women 
from disclosing their status or taking HAART is fear of 
being identified as an AIDS patient by community members, 
as indicated in the following: “People fear being identified 
because if they saw her at the clinic then people will start 
saying so and so family is all sick .”
Fear of serostatus disclosure
Many men indicated that they would withhold a positive 
diagnosis from their partners. A few men explained that if 
diagnosed positive, partner disclosure would be contingent on 
their partner’s diagnosis. They explained that if their partner 
revealed a discordant diagnosis, they would be more likely 
to keep their positive status a secret:
  “For me I was thinking that maybe I can go for testing 
first before the woman goes there and I test HIV-positive 
and I fear to tell her and when she goes there afterwards 
and she tests HIV-negative, then for me I will fear to tell 
her.
  I may inform her [of my HIV-positive status], and I put 
all my trust in her but when she goes and tests and finds 
herself HIV-negative, as I trust her I may not tell her 
instead I will keep on using a condom.”
Both respondents above communicated that the act of 
disclosure to be reliant upon their partner’s diagnosis. These 
comments implicitly assume that partners are not very open 
about their test results, and perpetuate secrecy between 
partners and compromise treatment uptake. Most men also 
cited a fear of abandonment as the primary motivation for 
partner nondisclosure:
	 “I can’t tell her, she will run away and leave me with the 
children.”
	 “If you the man brought the idea of testing, the woman 
will say that it means you are sick. She will start 
  suspecting you to be HIV positive and she might even 
run away from you.”
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The most common solution offered was that couples should 
be counseled and tested together. Participants suggested that 
this would promote understanding and reduce   nondisclosure 
among couples:
	 “For me I say there should be an understanding between 
the two and they both test and in case they are both sick 
of this disease they start the treatment.”
	 “I think with this issue of testing – it is better the two 
people be true to each other, both go and test and if they 
are to start the dose they both start that can benefit both 
of them.”
When we compared these responses about barriers to 
HAART uptake with those already published for women,16 
both groups agreed that the stigma of HIV and risk of dis-
closure of the diagnosis were formidable barriers to HAART 
access and uptake by pregnant/postnatal women. However, we 
also observed striking differences in their responses on what 
constituted barriers to HAART. Economic factors were at the 
top of the women’s list, whereas this barrier was not significant 
for men. Women also mentioned barriers for HAART access 
were their personal well being, eg, being too sick to go to the 
clinic or the belief that if they do not have clinical symptoms 
due to HIV , they do not need HAART. Health care-related 
factors constituting barriers to HAART, such as long waiting 
times at the clinic and unfriendly staff, did not feature in the 
male focus group discussions. While men tended to dwell on 
their low HAART knowledge, women did not mention this 
at all. Furthermore, lack of involvement in pregnancy and 
reproductive issues on the part of men was not referred to 
by the women. Similarly, joint counseling of both male and 
female partners during prenatal clinic visits was an important 
strategy for education about HAART expressed by men, but 
was not expressed by women in our previous study.
Discussion
This exploratory qualitative study provides an insight into the 
male perspective on the cultural context of locally perceived 
barriers to accessing HAART by pregnant/postnatal women 
attending the PMTCT-Plus program at the main regional 
hospital in Kabarole District.
Considering the drastically low coverage of HAART 
treatment among pregnant/postnatal women in Uganda and 
other developing countries, this study addresses a high priority 
research/knowledge gap in HIV/AIDS care and   prevention. 
Given that pregnant/postnatal women who are successful 
on HAART have significant health benefits, as well as a 
reduced risk of transmitting HIV to their offspring,20–22 the 
benefits of this program are multiple. Extending beyond the 
well being of infants and family members, this program is 
a huge investment in the health of women themselves. This 
study is one of few that have investigated both male and 
female perceptions of HAART treatment in the context of 
one selected PMTCT-Plus program. This approach enabled 
us to contrast male and female responses and provide a more 
indepth description on issues surrounding the low uptake of 
HAART by pregnant/postnatal women in this area.
Lack of knowledge on the part of men about HAART 
and services for pregnant/postnatal women was expressed 
by all participants, and was always a source of complaint in 
the discussions. This finding reflects the fact that although 
men are often excluded from reproductive health programs 
and counseling, they have a strong desire to be included in 
these services. This is also supported by men’s suggestion 
for couples counseling in PMTCT-Plus clinics, which may 
not have been effectively promoted in the study region. This 
willingness to participate is consistent with other studies from 
Uganda and East Africa.14 Surprisingly, although fear of HIV 
serostatus disclosure to one’s partner frequently surfaced as 
a barrier to HAART for pregnant/postnatal women in our 
study,16 lack of couples counseling was not identified as an 
issue by women. Lack of couples counseling in PMTCT-Plus 
programs has been identified mainly as a shortcoming on the 
part of service providers,23–25 but our findings suggest that 
women themselves may not view it as a deficit, although 
men do.
The main barrier to uptake of HAART by pregnant 
women expressed by men was fear of serostatus disclosure 
to their partners. They explained that women may find it 
impossible to hide their medication from their partners at 
home nor could they avoid being seen by neighbors or friends 
at the HAART clinics. This indicates that if an atmosphere of 
distrust in regard to HIV infection exists between partners, 
women may opt out of treatment because they see the risk of 
being identified as HIV-positive as too high. While stigma-
tization against persons with HIV has declined in the study 
area, it is still a reminder that stigma against HIV remains a 
serious impediment to HAART uptake among HIV-infected 
persons. The fear of disclosure of a positive HIV status to 
a partner was discussed thoroughly in all the focus group 
discussions and was believed to be widely prevalent, which 
is consistent with the literature.14,15,26,27
Comparison of our male and female study respondents 
revealed two surprising results. Men reported a strong desire 
to be involved in reproductive services, such as HIV testing 
and HAART for pregnant/postnatal women. In contrast, in 
the women’s interviews, male participation was completely 
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absent from the discussion surrounding barriers to HAART. 
It was the men, rather than the women, who wanted increased 
opportunities for men’s involvement in voluntary testing and 
couples counseling for HIV and PMTCT-Plus. These results 
raise a few larger questions.
Could it be that women do not want men to be part of 
their reproductive care and instead prefer to keep it as a 
women’s issue? Or could it be that this question of male 
involvement was never explored with women, and women 
assume that men do not want to attend PMTCT counseling 
or reproductive health care services? Given that health ser-
vices struggle to involve more men in female reproductive 
health care mainly by reorienting and retraining health care 
providers,23–25 the more important step could be to educate, 
discuss with, and sensitize women towards the goal of 
reproductive care in which both the male and female partner 
take part and share responsibilities. This important question 
warrants further investigation, and the results should be 
considered when developing educational programs for HIV 
treatment and prevention.
Given HIV/AIDS disclosure for pregnant women is so 
very risky (eg, abuse or abandonment), is couples   counseling 
at the pregnancy stage already too late? We should aim 
for couples counseling on reproductive health, including 
  disclosure of HIV serostatus, well before a woman has 
to cope with pregnancy in a relationship. These findings 
  reinforce our previously published recommendations that 
the earlier HAART education, treatment, and couples 
  counseling can be provided, the better. Accelerating the 
uptake of HAART among pregnant women is critical, given 
the current suboptimal HAART coverage among pregnant/
postnatal women in Uganda and elsewhere.
The importance of dealing with nondisclosure of an 
HIV-positive status in couples in this cultural setting has 
to be fully recognized. It is likely that intervention at the 
individual level (education) and interpersonal level (couples 
counseling) alone may not be sufficient to achieve any 
improvement. Intervention at the societal/structural level by 
education programs in communities at large is also required 
to improve societal acceptance of persons living with HIV , to 
enhance spousal responsibility for their partner’s health, to 
promote gender equality, and to counteract cultural beliefs 
about reproductive care being solely the responsibility of 
women.
Limitations
Because this was a qualitative study, the results cannot be 
generalized to populations outside of the Ugandan context. 
Secondly, given the sensitive nature of the topic, social 
desirability bias cannot be excluded. Interviewers trained in 
qualitative methods were used to reduce this potential bias. 
Finally, our data were collected in 2006, although given 
that little has changed in regard to HAART treatment for 
pregnant women since then, the results of this study continue 
to be relevant.
Conclusion
This study is very important for operational direction and 
improvement in service delivery since no other literature is 
available on this topic in sub-Saharan Africa. As a society, 
if men were more involved in reproductive health with 
their partners, and women would accept this approach, then 
couples could realize the significant benefits of a healthier, 
open approach to reproduction, including improved uptake 
of PMTCT-Plus services.
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